Rezolute (RZLT) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed Rezolute (RZLT) over the past year, gaining 52.3% versus a loss of 50.0%. Over five years, RZLT leads with a -34.1% price change compared with -67.4% for TECX. Tectonic Therapeutic is the larger company by market cap ($444.0 million vs $423.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RZLT | TECX |
|---|---|---|
| Share price | $4.38 | $22.71 |
| Market cap | $423.64M | $443.97M |
| 1-day change | +1.39% | +1.34% |
| YTD return | +85.59% | +8.87% |
| 1-year return | -50.00% | +52.31% |
| 5-year return | -34.14% | -67.37% |
| EPS (TTM) | $-0.75 | $-4.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.46 | $39.53 |
| 52-week low | $1.07 | $15.32 |
| Distance from 52-week high | -61.77% | -42.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +123.74% | +237.43% |
| Average volume | 1.48M | 219.12K |
| Shares outstanding | 96.72M | 19.55M |
| Employees | 58 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed RZLT by 102.3 percentage points over the past year.
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
RZLT vs TECX FAQ
Which is bigger, Rezolute or Tectonic Therapeutic?
Tectonic Therapeutic (TECX) is larger, with a market capitalization of $443.97M compared with $423.64M for Rezolute (RZLT).
Which stock has performed better over the past year, RZLT or TECX?
TECX returned +52.31% over the past 12 months, compared with -50.00% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Rezolute and Tectonic Therapeutic in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Rezolute and Biotechnology: Biological Products (No Diagnostic Substances) for Tectonic Therapeutic.